Pseudoginsenoside RT4
Based on 1 Customer Validation
Pseudoginsenoside RT4 is an orally active anti-inflammatory agent. Pseudoginsenoside RT4 can be isolated from Panax pseudoginseng subsp. Himalaicus, Panax vietnamensis Ha et Grushv, and Panax quinquefolius L. Pseudoginsenoside RT4 reduces the levels of TNF-α, IL-6, and IL-1β, elevates the level of IL-10, improves the histopathological features of colon tissue, maintains the ultrastructure of colonic epithelium, protects the integrity of cell monolayers, increases the expression of tight junction proteins, raises the total content of short-chain fatty acids, corrects intestinal flora disorder, reduces the disease activity index score, restores colon length, and decreases the spleen index. Pseudoginsenoside RT4 exhibits hepatoprotective effects. Pseudoginsenoside RT4 can be used in studies related to ulcerative colitis.
For research use only. We do not sell to patients.
- Purity: 97.05%
- CAS No.: 98474-77-2
- Formula: C36H62O10
- Molecular Weight:654.87
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-6 |
IL-1β |
IL-10 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
74.8 μM
Compound: 4
|
Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs
Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs
|
[PMID: 11325227] |
Pseudoginsenoside RT4 (4-16 µg/mL; 18 h) protects LPS-induced Caco-2 cell epithelial barrier damage by down-regulating pro-inflammatory cytokines, increasing TEER values, and enhancing tight-junction protein expression, with the strongest effects seen at 16 µg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Caco-2
-
Concentration:4-16 µg/mL (anti-inflammatory/barrier protection assay); 0-64 µg/mL (cell viability assay)
-
Incubation Time:18 h (anti-inflammatory/barrier protection assay); 4 h (cell viability assay)
-
Result:Maintained cell viability above 80% at 4, 8, and 16 µg/mL.
Dose-dependently down-regulated levels of pro-inflammatory factors TNF-α, IL-6, and IL-1β.
Significantly reduced all three pro-inflammatory factors at 8 and 16 µg/mL.
Specifically reduced IL-6 levels at 4 µg/mL.
Increased TEER values compared to the LPS-induced model group at 16 µg/mL.
Dose-dependently increased the expression and restored the membrane distribution of tight-junction proteins ZO-1, occludin, claudin-1, and E-cadherin at 4, 8, and 16 µg/mL.
| Species | Dose | Route | AUC0-t | AUC0-∞ | T1/2 | Tmax | Vd | CL | Cmax | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.g. | 991.55 h·μg/L | 1139.92 h·μg/L | 4.67 h | 1.50 h | 61.91 L/kg | 9.12 L/h/kg | 165.13 μg/L | / |
| Mice[1] | 20 mg/kg | i.g. | 2438.90 h·μg/L | 2698.59 h·μg/L | 6.29 h | 1.17 h | 71.24 L/kg | 8.04 L/h/kg | 295.59 μg/L | / |
| Mice[1] | 40 mg/kg | i.g. | 5288.20 h·μg/L | 5993.63 h·μg/L | 7.17 h | 1.33 h | 71.60 L/kg | 7.20 L/h/kg | 658.65 μg/L | 18.90 % |
| Mice[1] | 2 mg/kg | i.v. | 1246.37 h·μg/L | 1380.43 h·μg/L | 2.24 h | 0.03 h | 4.57 L/kg | 1.51 L/h/kg | 1970.34 μg/L | / |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (male, 6-7-week-old, DSS-induced ulcerative colitis)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.g.; daily; 3 days
-
Result:Reduced disease activity index (DAI) scores at 20 mg/kg and 40 mg/kg doses.
Increased body weight compared to the model group at 40 mg/kg dose.
Lengthened colon length at 20 mg/kg and 40 mg/kg doses; showed no statistically significant effect on colon length at 10 mg/kg dose.
Lowered spleen index in a dose-dependent manner across all three doses.
Decreased levels of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in serum and colon, and increased levels of anti-inflammatory cytokine IL-10 in serum and colon at 40 mg/kg dose.
Decreased levels of TNF-α, IL-6, and IL-1β in serum and colon, and increased colon IL-10 levels at 20 mg/kg dose.
Decreased levels of TNF-α, IL-6, and IL-1β in colon tissue at 10 mg/kg dose.
Restored total short-chain fatty acid (SCFA) content in cecal contents toward normal levels across all three doses.
Improved colonic histopathology in a dose-dependent manner: partially restored colonic crypt structure and reduced inflammatory infiltration at 10 mg/kg dose; clearly restored crypt structure and quantity and reduced inflammation at 20 mg/kg dose; restored crypt structure and quantity to near-normal levels with minimal inflammatory cell infiltration at 40 mg/kg dose.
Restored the ultrastructure of colonic mucosal epithelial cells in a dose-dependent manner, with 40 mg/kg dose maintaining near-normal microvilli arrangement and no organelle degeneration.
Increased gut microbiota operational taxonomic unit (OTU) count from 4677 (model group) to 7228, restored Shannon index to near-normal levels, and shifted gut microbiota structure toward that of normal mice at 40 mg/kg dose.
Normalized phylum-level abundances (reduced Acidobacteria, Proteobacteria, Epsilonbacteraeota, Actinobacteria; increased Tenericutes, Bacteroidetes) and genus-level abundances (reduced Escherichia-Shigella, Bacteroides; increased Alloprevotella, Rikenellaceae RC9 gut group, Odoribacter, Alistipes, Lactobacillus) at 40 mg/kg dose.
Chemical Information
-
CAS No. 98474-77-2
-
Appearance Solid
-
Molecular Weight 654.87
-
Formula C36H62O10
-
Color White to off-white
-
SMILES
C[C@]12[C@]3([C@@]([C@@H](C[C@]1([H])[C@@]4([C@@](C(C)([C@H](CC4)O)C)([H])[C@H](C2)O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)C)O)([H])[C@]([C@]6(O[C@@H](CC6)C(C)(O)C)C)([H])CC3)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pseudoginsenoside RT4 Related Classifications
HY-N17685 Related Classifications
Powered by Bioz